|
1
|
Lam EW, Brosens JJ, Gomes AR and Koo CY:
Forkhead box proteins: tuning forks for transcriptional harmony.
Nat Rev Cancer. 13:482–495. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carlsson P and Mahlapuu M: Forkhead
transcription factors: key players in development and metabolism.
Dev Biol. 250:1–23. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Laoukili J, Stahl M and Medema RH: FoxM1:
at the crossroads of ageing and cancer. Biochim Biophys Acta.
1775:92–102. 2007.PubMed/NCBI
|
|
4
|
Major ML, Lepe R and Costa RH: Forkhead
box M1B transcriptional activity requires binding of Cdk-cyclin
complexes for phosphorylation-dependent recruitment of p300/CBP
co-activators. Mol Cell Biol. 24:2649–2661. 2004. View Article : Google Scholar
|
|
5
|
Teh MT, Wong ST, Neill GW, Ghali LR,
Philpott MP and Quinn AG: FOXM1 is a downstream target of Gli1 in
basal cell carcinomas. Cancer Res. 62:4773–4780. 2002.PubMed/NCBI
|
|
6
|
Penzo M, Massa PE, Olivotto E, et al:
Sustained NF-κB activation produces a short-term cell proliferation
block in conjunction with repressing effectors of cell cycle
progression controlled by E2F or FoxM1. J Cell Physiol.
218:215–227. 2009.
|
|
7
|
Jiang LZ, Wang P, Deng B, Huang C, Tang
WX, Lu HY and Chen HY: Overexpression of Forkhead Box M1
transcription factor and nuclear factor-κB in laryngeal squamous
cell carcinoma: a potential indicator for poor prognosis. Hum
Pathol. 42:1185–1193. 2011.
|
|
8
|
Bektas N, Haaf At, Veeck J, et al: Tight
correlation between expression of the Forkhead transcription factor
FOXM1 and HER2 in human breast cancer. BMC Cancer. 8:422008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Barsotti A and Prives C: Pro-proliferative
FoxM1 is a target of p53-mediated repression. Oncogene.
28:4295–4305. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rovillain E, Mansfield L, Caetano C, et
al: Activation of nuclear factor-kappa B signaling promotes
cellular senescence. Oncogene. 30:2356–2366. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Luscher-Firzlaff JM, Westendorf JM,
Zwicker J, et al: Interaction of the fork head domain transcription
factor MPP2 with the human papilloma virus 16 E7 protein:
enhancement of transformation and transactivation. Oncogene.
18:5620–5630. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McMurray HR, Nguyen D, Westbrook TF and
McAnce DJ: Biology of human papillomaviruses. Int J Exp Pathol.
82:15–33. 2001. View Article : Google Scholar
|
|
13
|
Anders L, Ke N, Hydbring P, et al: A
systematic screen for CDK4/6 substrates links FOXM1 phosphorylation
to senescence suppression in cancer cells. Cancer Cell. 20:620–634.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bhat UG, Jagadeeswaran R, Halasi M and
Gartel AL: Nucleophosmin interacts with FOXM1 and modulates the
level and localization of FOXM1 in human cancer cells. J Biol Chem.
286:41425–41433. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
McGovern UB, Francis RE, Peck B, et al:
Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast
cancer. Mol Cancer Ther. 8:582–591. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kalinichenko VV, Major ML, Wang X, et al:
Foxm1b transcription factor is essential for development of
hepatocellular carcinomas and is negatively regulated by the p19ARF
tumor suppressor. Genes Dev. 18:830–850. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tan Y, Raychaudhuri P and Costa RH: Chk2
mediates stabilization of the FoxM1 transcription factor to
stimulate expression of DNA repair genes. Mol Cell Biol.
27:1007–1016. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Feng Y, Wang L, Zeng J, et al: FoxM1 is
overexpressed in Helicobacter pylori-induced gastric
carcinogenesis and is negatively regulated by miR-370. Mol Cancer
Res. 11:834–844. 2013.
|
|
19
|
Li J, Wang Y, Luo J, Fu Z, Ying J, Yu Y
and Yu W: miR-134 inhibits epithelial to mesenchymal transition by
targeting FOXM1 in non-small cell lung cancer cells. FEBS Lett.
586:3761–3765. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin PC, Chiu YL, Banerjee S, et al:
Epigenetic repression of miR-31 disrupts androgen receptor
homeostasis and contributes to prostate cancer progression. Cancer
Res. 73:1232–1244. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ke Y, Zhao W, Xiong J and Cao R: miR-149
inhibits non-small-cell lung cancer cells EMT by targeting FOXM1.
Biochem Res Int. 2013:5067312013.PubMed/NCBI
|
|
22
|
Nakamura S, Hirano I, Okinaka K, et al:
The FOXM1 transcriptional factor promotes the proliferation of
leukemia cells through modulation of cell cycle progression in
acute myeloid leukemia. Carcinogenesis. 31:2012–2021. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang X, Zeng J, Zhou M, et al: The tumor
suppressive role of miRNA-370 by targeting FoxM1 in acute myeloid
leukemia. Mol Cancer. 11:562012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhou M, Zeng J, Wang X, et al: MiR-370
sensitizes chronic myeloid leukemia K562 cells to homoharringtonine
by targeting Forkhead box M1. J Transl Med. 11:2652013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mencalha AL, Binato R, Ferreira GM, Du
Rocher B and Abdelhay E: Forkhead box M1 (FoxM1) gene is a new
STAT3 transcriptional factor target and is essential for
proliferation, survival and DNA repair of K562 cell line. PLoS One.
7:e481602012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu LL, Zhang DH, Mao X, Zhang XH and
Zhang B: Over-expression of FoxM1 is associated with adverse
prognosis and FLT3-ITD in acute myeloid leukemia. Biochem Biophys
Res Commun. 446:280–285. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yang J and Hung MC: A new fork for
clinical application: targeting forkhead transcription factors in
cancer. Clin Cancer Res. 15:752–757. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Brunet A, Bonni A, Zigmond MJ, et al: Akt
promotes cell survival by phosphorylating and inhibiting a Forkhead
transcription factor. Cell. 96:857–868. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu MC, Lee DF, Xia W, et al: IκB kinase
promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell.
117:225–237. 2004.
|
|
30
|
Yang JY, Zong CS, Xia W, et al: ERK
promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated
degradation. Nat Cell Biol. 10:138–148. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kong W, He L, Coppola M, Guo J, Esposito
NN, Coppola D and Cheng JQ: MicroRNA-155 regulates cell survival,
growth, and chemosensitivity by targeting FOXO3a in breast cancer.
J Biol Chem. 285:17869–17879. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang A, Ma J, Wu M, et al: Aberrant
microRNA-182 expression is associated with glucocorticoid
resistance in lymphoblastic malignancies. Leuk Lymphoma.
53:2465–2473. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liao WT, Li TT, Wang ZG, et al:
microRNA-224 promotes cell proliferation and tumor growth in human
colorectal cancer by repressing PHLPP1 and PHLPP2. Clin Cancer Res.
19:4662–4672. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Senyuk V, Zhang Y, Liu Y, et al: Critical
role of miR-9 in myelopoiesis and EVI1-induced leukemogenesis. Proc
Natl Acad Sci USA. 110:5594–5599. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen L, Tang Y, Wang J, Yan Z and Xu R:
miR-421 induces cell proliferation and apoptosis resistance in
human nasopharyngeal carcinoma via downregulation of FOXO4. Biochem
Biophys Res Commun. 435:745–750. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
So CW and Cleary ML: Common mechanism for
oncogenic activation of MLL by forkhead family proteins. Blood.
101:633–639. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fernández de Mattos S, Essafi A, Soeiro I,
et al: FoxO3a and BCR-ABL regulate cyclin D2 transcription through
a STAT5/BCL6-dependent mechanism. Mol Cell Biol. 24:10058–10071.
2004.PubMed/NCBI
|
|
38
|
Birkenkamp KU, Essafi A, van der Vos KE,
et al: FOXO3a induces differentiation of Bcr-Abl-transformed cells
through transcriptional down-regulation of Id1. J Biol Chem.
282:2211–2220. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ghaffari S, Jagani Z, Kitidis C, Lodish HF
and Khosravi-Far R: Cytokines and BCR-ABL mediate suppression of
TRAIL-induced apoptosis through inhibition of forkhead FOXO3a
transcription factor. Proc Natl Acad Sci USA. 100:6523–6528. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Essafi A, Fernandez de Mattos S, Hassen
YA, et al: Direct transcriptional regulation of Bim by FoxO3a
mediates STI571-induced apoptosis in Bcr-Abl-expressing cells.
Oncogene. 24:2317–2329. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jagani Z, Song K, Kutok JL, et al:
Proteasome inhibition causes regression of leukemia and abrogates
BCR-ABL-induced evasion of apoptosis in part through regulation of
forkhead tumor suppressors. Cancer Res. 69:6546–6555. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Scheijen B, Ngo HT, Kang H and Griffin JD:
FLT3 receptors with internal tandem duplications promote cell
viability and proliferation by signaling through Foxo proteins.
Oncogene. 23:3338–3349. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Brandts CH, Sargin B, Rode M, et al:
Constitutive activation of Akt by Flt3 internal tandem duplications
is necessary for increased survival, proliferation, and myeloid
transformation. Cancer Res. 65:9643–9650. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chapuis N, Park S, Leotoing L, et al: IκB
kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity
in acute myeloid leukemia. Blood. 116:4240–4250. 2010.
|
|
45
|
Dahia PL, Aguiar RC, Alberta J, et al:
PTEN is inversely correlated with the cell survival factor Akt/PKB
and is inactivated via multiple mechanisms in haematological
malignancies. Hum Mol Genet. 8:185–193. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Vazquez F and Sellers WR: The PTEN tumor
suppressor protein: an antagonist of phosphoinositide 3-kinase
signaling. Biochim Biophys Acta. 1470:M21–M35. 2000.PubMed/NCBI
|
|
47
|
Hussain AR, Al-Rasheed M, Manogaran PS,
Al-Hussein KA, Platanias LC, Al Kuraya K and Uddin S: Curcumin
induces apoptosis via inhibition of PI3′-kinase/AKT pathway in
acute T cell leukemias. Apoptosis. 11:245–254. 2006.PubMed/NCBI
|
|
48
|
Oteiza A and Mechti N: The human T-cell
leukemia virus type 1 oncoprotein tax controls forkhead box O4
activity through degradation by the proteasome. J Virol.
85:6480–6491. 2011. View Article : Google Scholar
|
|
49
|
Hui RC, Francis RE, Guest SK, et al:
Doxorubicin activates FOXO3a to induce the expression of multidrug
resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer
Ther. 7:670–678. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hui RC, Gomes AR, Constantinidou D, et al:
The forkhead transcription factor FOXO3a increases
phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic
cells through induction of PIK3CA expression. Mol Cell Biol.
28:5886–5898. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Naka K, Hoshii T, Muraguchi T, et al:
TGF-β-FOXO signaling maintains leukaemia-initiating cells in
chronic myeloid leukaemia. Nature. 463:676–680. 2010.
|
|
52
|
Duy C, Hurtz C, Shojaee S, et al:
BCL6 enables Ph+ acute lymphoblastic leukaemia
cells to survive BCR-ABL1 kinase inhibition. Nature.
473:384–388. 2011. View Article : Google Scholar
|
|
53
|
Hurtz C, Hatzi K, Cerchietti L, et al:
BCL6-mediated repression of p53 is critical for leukemia stem cell
survival in chronic myeloid leukemia. J Exp Med. 208:2163–2174.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sykes SM, Lane SW, Bullinger L, et al:
AKT/FOXO signaling enforces reversible differentiation blockade in
myeloid leukemias. Cell. 146:697–708. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ausserlechner MJ, Salvador C, Deutschmann
A, et al: Therapy-resistant acute lymphoblastic leukemia (ALL)
cells inactivate FOXO3 to escape apoptosis induction by TRAIL and
Noxa. Oncotarget. 4:995–1007. 2013.PubMed/NCBI
|
|
56
|
Bhat UG, Halasi M and Gartel AL: Thiazole
antibiotics target FoxM1 and induce apoptosis in human cancer
cells. PLoS One. 4:e55922009. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bhat UG, Halasi M and Gartel AL: FoxM1 is
a general target for proteasome inhibitors. PLoS One. 4:e65932009.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Nakamura S, Yamashita M, Yokota D, et al:
Development and pharmacologic characterization of deoxybromophospha
sugar derivatives with antileukemic activity. Invest New Drugs.
28:381–391. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Gusarova GA, Wang IC, Major ML,
Kalinichenko VV, Ackerson T, Petrovic V and Costa RH: A
cell-penetrating ARF peptide inhibitor of FoxM1 in mouse
hepatocellular carcinoma treatment. J Clin Invest. 117:99–111.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Essafi M, Baudot AD, Mouska X, Cassuto JP,
Ticchioni M and Deckert M: Cell-penetrating TAT-FOXO3 fusion
proteins induce apoptotic cell death in leukemic cells. Mol Cancer
Ther. 10:37–46. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kelly KR, Nawrocki ST, Espitia CM, et al:
Targeting Aurora A kinase activity with the investigational agent
alisertib increases the efficacy of cytarabine through a
FOXO-dependent mechanism. Int J Cancer. 131:2693–2703. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Teh MT, Hutchison IL, Costea DE, et al:
Exploiting FOXM1-orchestrated molecular network for early squamous
cell carcinoma diagnosis and prognosis. Int J Cancer.
132:2095–2106. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Cheong JW, Eom JI, Maeng HY, Lee ST, Hahn
JS, Ko YW and Min YH: Constitutive phosphorylation of FKHR
transcription factor as a prognostic variable in acute myeloid
leukemia. Leuk Res. 27:1159–1162. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kornblau SM, Singh N, Qiu Y, Chen W, Zhang
N and Coombes KR: Highly phosphorylated FOXO3A is an adverse
prognostic factor in acute myeloid leukemia. Clin Cancer Res.
16:1865–1874. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Dewar R, Chen ST, Yeckes-Rodin H, Miller K
and Khosravi-Far R: Bortezomib treatment causes remission in a Ph+
ALL patient and reveals FoxO as a theranostic marker. Cancer Biol
Ther. 11:552–558. 2011. View Article : Google Scholar : PubMed/NCBI
|
